Program
Brentuximab Vedotin
Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.
Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.
Drug pageBrentuximab Vedotin: every studyAll 154 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 241 open or running | phase 3since Apr 6, 2010 | Feb 1, 2007 | none ahead |
| Takedaits history only | 113 open or running | phase 4since Jul 1, 2013 | Dec 12, 2011 | Mar 31, 2028phase 4 · NCT06831370 |
| Bristol-Myers Squibb | 20 open or running | phase 3since May 1, 2017 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2015First study: phase 2 study in Non-Hodgkin's DiseaseFirst studyNCT02581631 · 145 enrolled · United States, Canada, France and more
- May 1, 2017Phase 3 study in Hodgkin DiseaseNCT03138499 · 23 enrolled · United States, Japan, Puerto Rico
TargetBeta
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule
Studies
All 2 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico | 3 | Terminated | Feb 22, 2021 | 23 |
| NCT02581631Non-Hodgkin's Disease · United States, Canada, France and more | 2 | Completed | Jan 16, 2020 | 145 |
How it is read
Names in the registry
- “brentuximab vedotin”, 27 entries
- “Brentuximab vedotin”, 7 entries
- “Brentuximab Vedotin”, 7 entries
- “SGN-35”, 2 entries
- “Brentuximab vedotin and rifampicin”, 1 entry
Conditions, from the studies’ own filings
- Hodgkin Disease, 18 studies
- Lymphoma, Large-Cell, Anaplastic, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Lymphoma, T-Cell, Peripheral, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.